• J Levitsky, R N Formica, R D Bloom, M Charlton, M Curry, J Friedewald, J Friedman, D Goldberg, S Hall, M Ison, T Kaiser, D Klassen, G Klintmalm, J Kobashigawa, A Liapakis, K O'Conner, P Reese, D Stewart, N Terrault, N Theodoropoulos, J Trotter, E Verna, and M Volk.
• Northwestern University, Chicago, IL.
• Am. J. Transplant. 2017 Nov 1; 17 (11): 2790-2802.

AbstractThe availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) infection has resulted in a profound shift in the approach to the management of this infection. These changes have affected the practice of solid organ transplantation by altering the framework by which patients with end-stage organ disease are managed and receive organ transplants. The high level of safety and efficacy of these medications in patients with chronic HCV infection provides the opportunity to explore their use in the setting of transplanting organs from HCV-viremic patients into non-HCV-viremic recipients. Because these organs are frequently discarded and typically come from younger donors, this approach has the potential to save lives on the solid organ transplant waitlist. Therefore, an urgent need exists for prospective research protocols that study the risk versus benefit of using organs for hepatitis C-infected donors. In response to this rapidly changing practice and the need for scientific study and consensus, the American Society of Transplantation convened a meeting of experts to review current data and develop the framework for the study of using HCV viremic organs in solid organ transplantation.© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

22 keywords...

hide…